Alzinova AB Logo

Alzinova AB

ALZ | ST

Overview

Corporate Details

ISIN(s):
SE0007413455
LEI:
549300K3IMVT20EK2S13
Country:
Sweden
Address:
Pepparedsleden 1, 431 83 MÖLNDAL
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Alzinova AB is a clinical-stage biopharmaceutical company specializing in the development of disease-modifying treatments for Alzheimer's disease. The company pioneers active and passive immunotherapies utilizing its proprietary AβCC Peptide™ technology platform. This approach specifically targets neurotoxic amyloid-beta (Aβ) oligomers, a key driver of the disease. Alzinova's lead candidate, ALZ-101, is a therapeutic vaccine in clinical development. The company's long-term goal is to develop a vaccine for both the treatment and prevention of Alzheimer's disease progression.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Alzinova AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Alzinova AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Alzinova AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-03 Tord Evert Sigfried Labuda Other Other 1,000,000 260,000.00 SEK
2025-04-03 Tord Evert Sigfried Labuda Other Buy 10,000 18,800.00 SEK
2025-04-02 Tord Evert Sigfried Labuda Other Buy 20,000 40,000.00 SEK
2024-12-16 Erik Kullgren Other Buy 10,000 34,400.00 SEK

Peer Companies

Company Country Ticker View
Genmab Logo
Develops antibody therapeutics for cancer and serious diseases using proprietary technology.
Denmark GMAB
Genomic Vision Logo
Develops DNA analysis tools using Molecular Combing for genetic research and diagnostics.
France GV
genOway Logo
Develops genetically engineered preclinical models for biopharma and academic research.
France ALGEN
GenSight Biologics S.A. Logo
Biopharma developing gene therapies for retinal neurodegenerative diseases and CNS disorders.
France SIGHT
Genxone Spolka Akcyjna Logo
A biotech firm offering nanopore DNA/RNA sequencing services and medical diagnostics.
Poland GX1
Guard Therapeutics International AB Logo
Clinical-stage biotech developing protein-based therapies for acute kidney injury.
Sweden GUARD
Gubra A/S Logo
Preclinical CRO and peptide drug developer for metabolic and fibrotic diseases.
Denmark GUBRA
Hamlet BioPharma AB Logo
Developing selective therapies for cancer and infections like bladder cancer and UTIs.
Sweden HAMLET
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops novel therapies for life-threatening blood disorders, cancers, and autoimmune diseases.
United Kingdom HEMO
Herantis Pharma Oyj Logo
Clinical-stage biotech developing therapies for neurodegenerative disorders like Parkinson's.
Finland HRTIS